Candel Therapeutics, Inc. (CADL): Total Liabilities
$73.27M
As of 2025-12-31
$82.02M
As of 2026-06-30
+34.7%
3-year compound annual growth
+41.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $73.27M | +80.7% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $40.54M | +42.5% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $28.46M | -5.1% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $29.98M | +19.6% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $25.07M | +96.1% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $12.78M | n/a | 2022-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | $73.27M | +80.7% |
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | $52.40M | -8.3% |
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | $42.92M | -24.4% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $20.97M | -8.6% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $4.96M | +46.5% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $113.26M | -40.6% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $12.41M | -36.4% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
Compare CADL, ABOS, KLRS, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗